Physician profile
Debra Guthrie
NPI 1215967740
$3,834.88
in general payments reported to CMS, 2019-2025
20 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $372 · 2021: $475 · 2022: $713 · 2023: $513 · 2024: $570 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.59 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $785.51 | 2020-2025 | Cequa, Xelpros |
| Allergan, INC. | $591.32 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $466.65 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $443.65 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $234.24 | 2019-2020 | |
| Alcon Vision LLC | $198.14 | 2022-2025 | Eysuvis, Tryptyr, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $173.26 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $124.78 | 2019 | |
| Sight Sciences, INC. | $123.42 | 2021-2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $121.74 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $109.91 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $84.57 | 2020-2022 | |
| Harrow Eye, LLC | $70.33 | 2025 | Vevye |
| Shire North American Group INC | $69.06 | 2019 | |
| Biotissue Holdings INC. | $61.02 | 2021-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $52.57 | 2020-2022 | |
| Thea Pharma INC. | $47.99 | 2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.18 | 2021 | |
| Astellas Pharma US INC | $24.80 | 2024 | Izervay |
| Amgen INC. | $21.74 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Guthrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.